John Hyngstrom,
MD
Languages Spoken: English
Dr. Hyngstrom is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the department of Surgery at the University of Utah. His medical practice is in general surgical oncology with a focus on melanoma and sarcoma, treating patients at the Huntsman Cancer Institute. His research interests include immunotherapy clinical trial development and survivorship issues in cancer patients. He currently serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on improving care for patients with advanced melanoma and other solid tumors. He is co-director of the physician-lead Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI. He also serves as the Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.
Dr. Hyngstrom earned his Bachelor of Arts degree from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from the University of Chicago Pritzker School of Medicine and completed his general surgery residency at the University of Chicago Medical Center. During his residency, he completed a two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. After finishing his general surgery training, Dr. Hyngstrom obtained his fellowship training in general surgical oncology at the University of Texas MD Anderson Cancer Center. Since 2012, he has worked as a faculty surgeon at the University of Utah Huntsman Cancer Institute, and as a contracted surgeon at Intermountain Medical Center.
Clinical Locations
801-587-4479
Board Certification and Academic Information
| Academic Departments | Surgery
-
Associate Professor (Clinical) |
| Academic Divisions | General Surgery |
| Board Certification | American Board of Surgery |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.7/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
March 19, 2022
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
March 17, 2022
HUNTSMAN CANCER CENTER
Dr. Hyngstrom not only knows his stuff, he is pleasant to work with.
UofU Patient
March 13, 2022
HUNTSMAN CANCER CENTER
Good
UofU Patient
March 12, 2022
HUNTSMAN CANCER CENTER
Anything that I could say is positive. Was interested and explained everything.
UofU Patient
February 18, 2022
HUNTSMAN CANCER CENTER
Went down there with one melanoma on my left shoulder got 3 d anda dye injection Dr took out 2lymph knodes and one out side pre cancer doing good now. Thanks to all Dr. Nurses & p.a. And other specialist .
UofU Patient
January 31, 2022
HUNTSMAN CANCER CENTER
They are all great
UofU Patient
December 18, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom is God-sent! As I navigate multiple surgeries with Metastatic Melanoma, the confidence I have in Dr. Hyngstrom's concern & expertise for me is exceptional. Having such a high level of care gives me hope & provides peace, heart & mind, for my journey with such a deadly cancer. Dr. Hyngstrom is a true blessing!
UofU Patient
December 06, 2021
HUNTSMAN CANCER CENTER
Very helpful best place ever
UofU Patient
December 01, 2021
HUNTSMAN CANCER CENTER
I had a lot of questions, some of them a bit complicated, and he took the time to answer them.
UofU Patient
November 25, 2021
HUNTSMAN CANCER CENTER
Follow up already planned
UofU Patient
November 11, 2021
HUNTSMAN CANCER CENTER
Great
UofU Patient
November 11, 2021
HUNTSMAN CANCER CENTER
They could not have been more caring and helpful! It was a very scary time and they gave me so much comfort and information
UofU Patient
November 02, 2021
HUNTSMAN CANCER CENTER
Doctor and all staff were very professional, and very nice!
UofU Patient
November 02, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom answered all questions from my husband and myself thoroughly, recognizing all concerns we had.
UofU Patient
November 02, 2021
HUNTSMAN CANCER CENTER
Was pleased with the entire staff and how smoothly everything went.
UofU Patient
October 25, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom and his PA, Liz are always so upfront and sincerely concerned with my health care and ongoing cancer issues. They are the BEST in my book!!!
UofU Patient
October 12, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
September 09, 2021
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
September 04, 2021
HUNTSMAN CANCER CENTER
All was helpful and kind.
UofU Patient
September 04, 2021
HUNTSMAN CANCER CENTER
Excellent
UofU Patient
September 04, 2021
HUNTSMAN CANCER CENTER
Very thorough
UofU Patient
August 30, 2021
HUNTSMAN CANCER CENTER
I've been a patient of Dr. Hyngstrom's for 5.5 years and would recommend him in a heartbeat. He's caring, knowledgeable, and skilled, and just overall superb.
UofU Patient
August 26, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom and his PA. Were amazing!
UofU Patient
July 17, 2021
HUNTSMAN CANCER CENTER
We talked for quite a long time but when I apologized for that he said it was not a problem at all. I felt that we discussed the peculiarities of my case thoroughly and well and my questions were answered as well as possible, considering the current state of research. The primary purpose of the visit, which was to understand the surgery option, was accomplished. We have since made the next treatment decision and this visit helped us do that.
UofU Patient
July 17, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
June 23, 2021
HUNTSMAN CANCER CENTER
I was pretty scared of.my appointment but when created.with your staff and my sister with help so very.much
UofU Patient
June 22, 2021
HUNTSMAN CANCER CENTER
Dr. Hyngstrom is always so easy to talk to and he is a great listener. He thoroughly and honestly discusses my cancer concerns with me. This is very much appreciated!
UofU Patient
May 20, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
May 20, 2021
HUNTSMAN CANCER CENTER
Dr. Hydstrom is a very caring and compassionate doctor. I feel very confident that I had the best care ever! The little things that make all the difference for me it was him simply acknowledging an old trauma and taking a second to look in my eyes and seeing "me". Grateful to have been with such a great team.
UofU Patient
May 11, 2021
HUNTSMAN CANCER CENTER
Dr. Hydstrom's is very kind and gentle with a beautiful bedside manner.
UofU Patient
April 29, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
April 17, 2021
HUNTSMAN CANCER CENTER
Our experiences were all great. Dr Hyngstrom and PA Liz (Elizabeth) were both extremely caring, knowledgeable, supportive, and thorough. They listened to us, did comprehensive exams, answered all our questions and concerns, and carefully helped us establish surveillance and follow up plans.
UofU Patient
April 01, 2021
HUNTSMAN CANCER CENTER
Everything was reviewed and answered well.
UofU Patient
March 29, 2021
HUNTSMAN CANCER CENTER
Physician called next day to follow-up on a concern he felt I should know about. Great discussion and came to a logical "next step" understanding.
UofU Patient
March 29, 2021
HUNTSMAN CANCER CENTER
I was very pleased with the courtesy of all staff
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
very respectful and down to a regular level. not arrogant, he was sweet
UofU Patient
March 18, 2021
HUNTSMAN CANCER CENTER
My case was a diagnostic dilemma that was discussed with all the pros and cons and my desires and requests were taken into consideration to make the best diagnostic plan. I am grateful for that.
UofU Patient
March 18, 2021
HUNTSMAN CANCER CENTER
The professionalism and care Dr. Hyngstrom and Liz always provide to me is nothing but the best. I appreciate their sincere concern for me and my melanoma related issues. They are both amazing!!
UofU Patient
March 12, 2021
HUNTSMAN CANCER CENTER
HYNGSTROM is AWESOME!!!!
UofU Patient
March 01, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
January 30, 2021
HUNTSMAN CANCER CENTER
Very good
UofU Patient
January 18, 2021
HUNTSMAN CANCER CENTER
There were no bad experience's
UofU Patient
January 16, 2021
HUNTSMAN CANCER CENTER
I hope nobody that I know has to see Dr. Hyngstrom, because that would mean they have cancer. But if somebody has cancer, I will definitely recommend his office.
UofU Patient
January 15, 2021
HUNTSMAN CANCER CENTER
Dr Hyngstrom called personally with the results.
UofU Patient
December 19, 2020
HUNTSMAN CANCER CENTER
I was impressed with everyone's concern and care they showed
UofU Patient
December 15, 2020
HUNTSMAN CANCER CENTER
Dr. Hyngstrom and Liz were amazing! They talked to me, explaining my lab results and their reasoning for additional biopsies. They both took their time to answer all of my questions and concerns and to provide me with the best possible care, which I always receive at HCI.
UofU Patient
December 11, 2020
HUNTSMAN CANCER CENTER
Great
UofU Patient
December 05, 2020
HUNTSMAN CANCER CENTER
Dr. H is, in my humble opinion as good and collaborative as I've ever experienced.
UofU Patient
October 21, 2020
HUNTSMAN CANCER CENTER
the visit seemed like it was a little more of get me in and out. i guess there was no issues or concerns but not much was said about it.
UofU Patient
October 08, 2020
HUNTSMAN CANCER CENTER
Dr Hyngstrom has been wonderful through my care. I felt cared for. I'm grateful to be able to say a final goodbye
Dr. Hyngstrom is an Associate Professor in the section of Surgical Oncology, division of General Surgery within the department of Surgery at the University of Utah. His medical practice is in general surgical oncology with a focus on melanoma and sarcoma, treating patients at the Huntsman Cancer Institute. His research interests include immunotherapy clinical trial development and survivorship issues in cancer patients. He currently serves as the site primary investigator at HCI on multiple therapeutic cooperative group and industry sponsored clinical trials focusing on improving care for patients with advanced melanoma and other solid tumors. He is co-director of the physician-lead Clinical Trials Research Group and the clinical lead of the Melanoma Disease Center at HCI. He also serves as the Surgery Chair of the Melanoma Working Group of the Southwest Oncology Cooperative Group through the NCI.
Dr. Hyngstrom earned his Bachelor of Arts degree from Washington University in St. Louis, Missouri. He earned his Doctor of Medicine from the University of Chicago Pritzker School of Medicine and completed his general surgery residency at the University of Chicago Medical Center. During his residency, he completed a two-year clinical research fellowship in surgical oncology and tumor immunology at the Surgery Branch of the NCI/NIH in Bethesda, Maryland. After finishing his general surgery training, Dr. Hyngstrom obtained his fellowship training in general surgical oncology at the University of Texas MD Anderson Cancer Center. Since 2012, he has worked as a faculty surgeon at the University of Utah Huntsman Cancer Institute, and as a contracted surgeon at Intermountain Medical Center.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Surgery
-
Associate Professor (Clinical) |
| Academic Divisions | General Surgery |
| Board Certification | American Board of Surgery |
Education History
| Fellowship | The University of Texas MD Anderson Cancer Center Surgical Oncology, Program Director: Jason Fleming, MD Fellow, 2012 |
| Residency | University of Chicago Medical Center, the Pritzker School of Medicine General Surgery, Program Director: Mitchell Posner, MD Resident, 2010 |
| Fellowship | National Cancer Institute, Surgery Branch Surgical Oncology Clinical Research, Program Director: Steven Rosenberg, MD PhD Fellow, 2007 |
| Professional Medical | The University of Chicago Pritzker School of Medicine Medicine M.D., 2003 |
| Undergraduate | Washington University Biology and History B.A., 1999 |
Selected Publications - Journal Articles
Journal Article
- Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, Anderson A, Chan E, Faries M, Ross MI (2021). Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med, 27(10), 1789-1796.
- Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, OShea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE (2021). Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma. Melanoma Res, 31(4), 378-388.
- Walker HR, Evans E, Nirula R, Hyngstrom J, Matsen C, Nelson E, Pickron B, Zurbuchen E, Morrow EH (2021). "I need to have a fulfilling job": A qualitative study of surgeon well-being and professional fulfillment. Am J Surg, 223, 6-11.
- Chick RC, Faries MB, Hale DF, Kemp Bohan PM, Hickerson AT, Vreeland TJ, Myers JW 3rd, Cindass JL, Brown TA 2nd, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Clifton GT, Park H, Sloan AJ, Wagner T, Peoples GE (2021). Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis. Cancer Med, 10(13), 4302-4311.
- Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 27(3), 555-559.
- Bleicher J, Asare EA, Flores S, Bowles TL, Bowen GM, Hyngstrom JR (2020). Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study. Am J Surg, 221(4), 844-849.
- Bleicher J, Cohan JN, Huang LC, Peche W, Pickron TB, Scaife CL, Bowles TL, Hyngstrom JR, Asare EA (2020). Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature. World J Gastroenterol, 27(3), 267-280.
- Bleicher J, Swords DS, Mali ME, McGuire L, Pahlkotter MK, Asare EA, Bowles TL, Hyngstrom JR (2020). Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. J Surg Oncol, 122(8), 1770-1777.
- Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol, 156(9), 1004-1011.
- Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL (2019). Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status. Melanoma Res, 30(2), 173-178.
- Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 59(4), 434-437.
- Park SH, Kwon OS, Park SY, Weavil JC, Hydren JR, Reese V, Andtbacka RHI, Hyngstrom JR, Richardson RS (2020). Vasodilatory and vascular mitochondrial respiratory function with advancing age: evidence of a free radically mediated link in the human vasculature. Am J Physiol Regul Integr Comp Physiol, 318(4), R701-R711.
- Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med, 8(18), 7637-7643.
- Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA (2018). Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol, 79(2), 238-244.
- Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.
- Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399.
- Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA (2014). Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol, 109(7), 652-8.
- Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN (8/23/2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res, 23(4), 290--7.
- Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN, Chang GJ (2012). Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol, 19(9), 2814-21.
Case Report
Letter
- Bilimoria KY, Russell MC, Hyngstrom J (2017). Melanoma Sentinel-Node Metastasis. [Letter to the editor]. N Engl J Med, 377(9), 891.
- Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D (2014). Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. [Letter to the editor]. J Am Acad Dermatol, 71(4), 835-8.
Other
- Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ (2021). Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer (9(10)). England.
- Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN (2013). Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res (23(4), pp. 290-7). England.